Airsculpt Technologies, Inc.
AIRSAbout the company
AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States and Canada. The company offers AirSculpt, a body contouring treatment that removes fat and tightens skin while sculpting targeted areas of the body in a minimally invasive procedure.
Investment snapshot
Positive
2
BUY / PASS
Neutral / negative
0 / 14
NEUTRAL / FAIL
Median fair value
$0.15
-82.7% vs price
Models with upside
0 / 17
Positive margin of safety
Key risk
No clean pass — all 13 investors flag at least one valuation criterion
Framework analysis
| Verdict | Meaning |
|---|---|
| BUY | Positive purchase signal: the framework's buy requirements are met. |
| PASS | The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state. |
| NEUTRAL | Neither a positive nor negative conclusion. It does not mean to hold an existing position. |
| FAIL | The company does not clear the framework's requirements. |
| Ranked | Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL. |
Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.
| Metric | Graham Defensive Value | Buffett Quality Compounder | Lynch GARP | Greenblatt Magic Formula | Piotroski F-Score | Dreman Contrarian Value | Munger Quality Focus | Pabrai Dhandho Framework | Akre Three-Legged Stool | Marks Risk-Aware Value | Ackman Activist Value | Templeton Global Bargain Hunter | Sleep Scale Economies Shared | Asness Systematic Factors | Neff Low-P/E Total Return | Schloss Asset-Value Discipline | O'Shaughnessy Systematic Factor Composite |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verdict | FAIL | FAIL | FAIL | FAIL · Rank #2401 (Top 77.5%) | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | PASS | PASS | FAIL | FAIL | FAIL | FAIL |
| Score | |||||||||||||||||
| Analysis | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… |
| Intrinsic Value (annual) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||
| Margin of Safety | N/A | N/A | N/A | N/A | N/A | N/A | -318.5% | N/A | N/A | N/A | -830.0% | N/A | N/A | N/A | N/A | N/A | N/A |
| Financial Basis | TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025 Latest source filing: 2026-11-06 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 Latest source filing: 2026-11-06 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30 Latest source filing: 2026-11-06 Score computed: 2026-11-14 | TTM ended 2026-09-30 Latest source filing: 2026-11-06 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-31 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01 Latest source filing: 2026-11-06 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-06 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-03-31 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-06 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 · Qualitative assessment Latest source filing: 2026-11-06 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01 Latest source filing: 2026-11-06 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-06 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-31 Score computed: 2026-11-14 | TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025 Latest source filing: 2026-11-06 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 Latest source filing: 2026-11-06 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-06 Score computed: 2026-11-14 | TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-11-06 Score computed: 2026-11-14 |
Where It Passes
Where It Falls Short
- Valuation0% pass✓ 7✗ 21▾
No clean pass — all 13 investors flag at least one valuation criterion
Price / 3-yr avg EPS✗Graham<= 15xPrice-to-Book Ratio0.6x✓Graham<= 1.5xP/E x P/B✗Graham<= 22.5Basic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)EBIT / Enterprise Value-8.4%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-8.4%, ROC=-76.4%✗GreenblattBoth EY > 10% and ROC > 25%Price / EPS✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)Price / (CFO / Shares)17.4x✗Dreman< 8xPrice / Book Value per Share0.6x✓Dreman< 1.2x✓Templeton< 1.5x✓SchlossP/B <= 0.80x (app cutoff)Valuation ReasonablenessOE Yield=-2.4%✗MungerP/E < 25 or Owner Earnings Yield > 5%P/E or FCF YieldFCF Yield=1.1%✗PabraiP/E < 15 or FCF Yield > 10%P/B or P/E vs. Historical AverageP/B=0.6x✓MarksP/E < 15 or P/B < 2.0Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePrice / FCF per Share78.0x✗Ackman<= 25Price vs. Trailing Low100% of trailing low ($0.84)✓Templeton<= 120% of trailing low (certified split-adjusted live window)Net income / market capitalization-15.19%; #4390/6340 (top 69.2%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionPositive book equity / market capitalization+1.7121; #788/6449 (top 12.2%)✓AsnessTop 30% of eligible cross-sectionPrice / Diluted EPS✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)(EPS CAGR % + Dividend Yield %) / P/E✗Neff> 0.7 (Neff's published traditional edge)Price / Tangible Book Value per ShareN/A (non-positive TBVPS)✗SchlossP/TBV <= 1.00x (app cutoff)Book Value per Share Change-9.4%✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)Revenue / market capitalization+2.3866; #957/5247 (top 18.2%)✗OshaughnessyTop 10% of eligible cross-section(Operating cash flow - capex) / market capitalization-4.10%; #2907/4519 (top 64.3%)✗OshaughnessyTop 10% of eligible cross-sectionTrailing six-month price return through the evaluation date-68.30%; #5622/6202 (top 90.6%)✗OshaughnessyTop 10% of eligible cross-section - Growth0% pass✓ 2✗ 11▾
No clean pass — all 8 investors flag at least one growth criterion
EPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passInventory Growth vs Revenue GrowthN/A (no inventory)✓LynchInventory growth < Revenue growthEPS Growth Direction$-0.01 (2021) -> $-0.19 (2025)✗DremanPositive over recent yearsEPS CAGR✗Dreman> 5% annualizedPositive Net Income Frequency2/7 years positive✗MarksPositive net income in >= 7 of last 10 years3yr Median Revenue Growth-7.9%✗Ackman>= 5%Positive EPS Growth Frequency1/4 years with positive EPS growth✗AckmanPositive EPS growth in >= 3 of last 5 years5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Revenue growth vs. gross and operating margin trendgross margin 62.3% -> 59.4%, operating margin 5.0% -> -7.6%✗SleepRevenue rising; gross margin flat or falling; operating margin holding5-year Revenue CAGR19.3%✓SleepCAGR > 7%3-5 Year Diluted EPS CAGR✗Neff7%-20% annualized - Efficiency0% pass✗ 11▾
All 8 investors flag AIRS's efficiency
Current Ratio0.85✗Graham>= 2.0ROIC (3-5 yr avg)0.8%✗Buffett> 10%ROIC - WACC-9.2%✗BuffettPositive (WACC = 10%)EBIT / (NWC + Net Fixed Assets)-76.4%✗Greenblatt> 25%Current Ratio Change YoY0.59 -> 0.55✗PiotroskiIncreased YoYRevenue / Total Assets Change YoY0.85x -> 0.81x✗PiotroskiImproved YoYCurrent Assets / Current Liabilities0.85✗Dreman> 1.5Return on Invested Capital-3.9%✗Munger> 15%ROIC (high and growing)FY2023: ROIC=5.0%; FY2024: ROIC=-0.8%; FY2025: ROIC=-6.4%✗AkreLatest 3 consecutive FYs: ROIC > 15% in eachReinvestment Rate x ROICN/A (non-positive net income)✗AkreReinvestment Rate * ROIC > 10%ROIC (5-year)0/5 years above 12% (latest -6.4%)✗SleepROIC > 12% in a majority of years - Valuation models0% pass✗ 2▾
AIRS overvalued: all 2 models price fair value below $0.84 (median $0.15)
Munger fair value$0.20✗Munger-318.5% margin vs $0.84Ackman fair value$0.09✗Ackman-830.0% margin vs $0.84 - Profitability6% pass✓ 3✗ 32▾
15 of 16 flag AIRS's profitability — Graham, Buffett, Lynch +12 more
Positive EPS (10 years)0/8 years positive✗GrahamPositive EPS every year for 10 yearsEPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthNet Income Positive (10+ years)2/8 years positive✗BuffettPositive every year for 10+ yearsROE (up to 5-year arithmetic mean)-7.4%✗Buffett> 15% arithmetic mean (app rule)Operating Margin (10-yr trend)-7.6% (latest)✗BuffettStable or rising over 10 yearsFree Cash Flow Proxy$-1.3M✗BuffettPositive and growingEarnings Variance (10-yr CoV)N/A (negative mean EPS)✗BuffettCoV < 0.3Retained Earnings Effectiveness✗Buffett$1 retained -> > $1 market value createdBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passROE-8.9%✗Lynch> 15%EBIT / Enterprise Value-8.4%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-8.4%, ROC=-76.4%✗GreenblattBoth EY > 10% and ROC > 25%Net Income / Total Assets-6.23%✗PiotroskiROA > 0ROA Change YoY-3.77% -> -6.23% (delta: -2.46%)✗PiotroskiCurrent ROA > Prior ROA(CFO / Total Assets) vs ROACFO/Assets=1.65%, ROA=-6.23%✓PiotroskiCFO/Assets > ROAGross Margin Change YoY60.5% -> 59.4%✗PiotroskiImproved YoYPre-Tax Income / Revenue-8.1%✗Dreman>= 8%Net Income / Shareholders' Equity-8.9%✗Dreman> 12%Margin of SafetyP/B=0.6x✓PabraiP/B < 1.5 or P/E < 15Return on Equity-9.6% (3-yr avg)✗AkreROE > 20% (3-year avg)Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePositive Net Income Frequency2/7 years positive✗MarksPositive net income in >= 7 of last 10 yearsOperating Income / Revenue-4.7%✗Ackman>= 15%Net Income / Shareholders Equity-8.9%✗Ackman>= 15%5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Operating Margin Trend5.0% (2023) -> -7.6% (2025)✗TempletonNon-negative operating-margin trend over 3 yearsRevenue growth vs. gross and operating margin trendgross margin 62.3% -> 59.4%, operating margin 5.0% -> -7.6%✗SleepRevenue rising; gross margin flat or falling; operating margin holdingNet income / market capitalization-15.19%; #4390/6340 (top 69.2%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionGross profit / total assets+48.12%; #708/3702 (top 19.1%)✓AsnessTop 30% of eligible cross-sectionNet income / positive book equity-8.87%; #3360/5226 (top 64.3%)✗AsnessTop 30% of eligible cross-sectionNegative 5-year standard deviation of ROA-0.0444; #2422/5884 (top 41.2%)✗AsnessTop 30% of eligible cross-section3-5 Year Diluted EPS CAGR✗Neff7%-20% annualizedPositive Diluted-EPS Years0/5 years positive✗Schloss>= 70% positive over 5-10 observed years (app rule) - Verdicts12% pass✓ 2✗ 15▾
Split decision: 14 FAIL · 2 PASS
Overall verdict✗GrahamFAIL (2/9)✗BuffettFAIL (0/9)✗LynchFAIL (1/7)✗GreenblattRank #2401✗PiotroskiFAIL (F-Score 3)✗DremanFAIL (2/11)✗MungerFAIL (1/4)✗PabraiFAIL (1/3)✗AkreFAIL (1/6)✗MarksFAIL (2/5)✗AckmanFAIL (2/9)✓TempletonPASS (4/8)✓SleepPASS (3/6)✗AsnessFAIL (Rank #1474/2370 (Top 62.2%))✗NeffFAIL (1/6)✗SchlossFAIL (3/7)✗OshaughnessyFAIL (Rank #955/963 (Top 99.2%)) - Cash Flow30% pass✓ 4✗ 8▾
7 of 10 flag AIRS's cash flow — Buffett, Lynch, Dreman +4 more
Free Cash Flow Proxy$-1.3M✗BuffettPositive and growingFCF Positive and Growing$-2.5M✗LynchPositive and growingOperating Cash Flow$3.1M✓PiotroskiCFO > 0(CFO / Total Assets) vs ROACFO/Assets=1.65%, ROA=-6.23%✓PiotroskiCFO/Assets > ROAPrice / (CFO / Shares)17.4x✗Dreman< 8xP/E or FCF YieldFCF Yield=1.1%✗PabraiP/E < 15 or FCF Yield > 10%FCF Positive6/7 years FCF positive✓MarksPositive FCF in majority of recent years(OCF - CapEx) / Market Cap-4.7%✗Ackman>= 4%Price / FCF per Share78.0x✗Ackman<= 25Positive Operating Cash Flow frequency7/7 years positive✓SleepPositive OCF in >= 70% of available yearsOperating Cash Flow - Capital Expenditures$-2.5M✗Neff> $0 (app proxy for a strong fundamental case)(Operating cash flow - capex) / market capitalization-4.10%; #2907/4519 (top 64.3%)✗OshaughnessyTop 10% of eligible cross-section - Debt & Leverage33% pass✓ 6✗ 9▾
8 of 12 flag AIRS's debt & leverage — Graham, Buffett, Lynch +5 more
Debt Levels0.35✓MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3LT Debt vs Net Current AssetsLT Debt $31.2M vs NCA $-4.2M✗GrahamLT Debt <= Net Current AssetsDebt/Equity & Interest CoverageD/E: 0.35, IC: -1.4x✗BuffettD/E < 0.5 AND Interest Coverage > 5xTotal Debt / Equity0.35✗Lynch< 0.33Cash - Long-term Debt$-16.0M✗LynchPositive preferredLT Debt / Total Assets Change30.76% -> 27.01%✓PiotroskiDecreased YoYCurrent Assets / Current Liabilities0.85✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)Total Debt / Shareholders' Equity0.35✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00xInterest Coverage & Debt/EBITDAIC=-1.4x, D/EBITDA=7.4x✗MarksInterest Coverage > 3x; Debt/EBITDA < 4xTotal Debt / Shareholders Equity0.35✓Ackman<= 1.0Negative debt-to-equity (higher means less debt)-0.3460; #2123/4210 (top 50.4%)✗AsnessTop 30% of eligible cross-section
Business & financials
Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.
Company Profile
Financial Snapshot
Shareholder Return
Fiscal 2025
Issued 10.0% of shares last year, 12.2% issued over two.
- Buybacks
- —
- Dividends
- $0
Company Financials
Latest TTM and quarters alongside annual years
TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.
The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.
| Metric | TTM · 2026-09-30 2025-10-01 – 2026-09-30 Sources · derived quarter valuesDerived from cumulative filings: revenue, net income, operating income, ebit, pre tax income, interest expense, operating cash flow, depreciation amortization, capex, dividends paid. | Q3 FY 2026 2026-07-01 – 2026-09-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, capex. | Q2 FY 2026 2026-04-01 – 2026-06-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, capex. | Q1 FY 2026 2026-01-01 – 2026-03-31 Sources | FY 2025Sources
| FY 2024Sources
| FY 2023Sources
| FY 2022Sources
| FY 2021Sources
|
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $61.9Mcurrent | -- | -- | -- | $191.4Mest. | $280.6Mest. | $416.9Mest. | $328.2Mest. | $784.5Mest. |
| Revenue | $147.7M↓6% | $31.9M↓9% | $42.9M↓3% | $39.4M | $151.8M↓16% | $180.3M↓8% | $195.9M↑16% | $168.8M↑27% | $133.3M |
| Operating Income | -$7.0M↑52% | -$4.1M↑58% | -$29.0K↓104% | -$1.8M↓13% | -$11.6M↓630% | -$1.6M↓116% | $9.7M↑314% | -$4.5M↓129% | $15.8M |
| Net Income | -$9.4M↑48% | -$7.2M↑25% | -$1.1M↓88% | -$2.4M↑16% | -$11.7M↓46% | -$8.0M↓89% | -$4.2M↑71% | -$14.7M↓239% | $10.6M |
| EPS (Diluted) | -- | $-0.10↑33% | $-0.02↓100% | $-0.03↑40% | $-0.19↓36% | $-0.14↓75% | $-0.08↑69% | $-0.26↓2500% | $-0.01 |
| Gross Margin | — | — | — | — | 59.4%↓2% | 60.5%↓3% | 62.3%↓1% | 62.8%↓6% | 66.6% |
| Operating Margin | -4.7%↑49% | -13.0%↑53% | -0.1%↓104% | -4.6%↓13% | -7.6%↓768% | -0.9%↓118% | 5.0%↑284% | -2.7%↓123% | 11.8% |
| ROE | -8.9%↑59% | — | — | — | -13.3%↓30% | -10.3%↓100% | -5.1%↑75% | -20.7%↓264% | 12.6% |
| Total Debt | $36.7M↓36% | $36.7M↓36% | $43.6M↓25% | $44.8M↓35% | $56.0M↓20% | $69.7M↓3% | $71.6M↓14% | $83.5M↑1% | $82.6M |
| Shareholders' Equity | $105.9M↑29% | $105.9M↑29% | $104.8M↑15% | $100.3M↑30% | $87.7M↑12% | $78.2M↓5% | $82.7M↑17% | $70.8M↓15% | $83.5M |
| Current Ratio | 0.85↑68% | 0.85↑68% | 0.79↑24% | 0.75↑31% | 0.55↓6% | 0.59↓25% | 0.79↑5% | 0.75↓58% | 1.79 |
| Debt / Equity | 0.35↓50% | 0.35↓50% | 0.42↓34% | 0.45↓50% | 0.64↓28% | 0.89↑3% | 0.87↓27% | 1.18↑19% | 0.99 |
| Operating Cash Flow | -$2.0M↓124% | -$3.5M↓1444% | -$1.2M↓125% | $5.3M↑507% | $3.1M↓73% | $11.3M↓53% | $24.0M↓2% | $24.4M↓8% | $26.6M |
| Free Cash Flow | -$2.5M↓203% | -$3.7M↓814% | -$1.5M↓131% | $5.2M↑605% | $692.0K↑126% | -$2.7M↓119% | $14.0M↑22% | $11.5M↓41% | $19.5M |
Score history
Historical Score Timeline
Industry peers
Industry Peers
Similar companies in Healthcare
AIRS vs Peers — Financial Grading
| Company | Market Cap | Price | Revenue | Net Income | ROE | D/E | Op. Margin | Curr. Ratio | Graham | Buffett | Lynch | Greenblatt | Piotroski | Dreman |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCA Healthcare, Inc.HCA | $104.2B | $499.05 | $75.6B | $6.8B | -112.6% | -7.71 | 13.0% | 0.97 | 1/9 | 5/9 | 3/7 | 1/3 | F-Score 6 | 4/11 |
| TENET HEALTHCARE CORPTHC | $22.8B | $286.03 | $21.3B | $2.4B | 56.1% | 3.12 | 16.5% | 1.76 | 1/9 | 4/9 | 3/7 | 3/3 | F-Score 6 | 5/11 |
| Guardant Health, Inc.GH | $20.5B | $151.70 | $982.0M | $416.3M | 419.2% | -15.14 | -44.5% | 4.84 | 2/9 | 1/9 | 1/7 | 0/3 | F-Score 5 | 2/11 |
| EXACT SCIENCES CORPEXAS | $20.0B | $104.91 | $3.2B | $207.9M | -8.7% | 0.00 | -6.4% | 2.43 | 2/9 | 1/9 | 3/7 | 0/3 | F-Score 7 | 3/11 |
| Fresenius Medical Care AGFMS | $11.4B | $22.03 | $23.1B | $1.1B | 7.4% | 0.81 | 9.3% | 1.26 | 5/9 | 2/9 | 1/7 | 0/3 | F-Score 8 | 5/11 |
| UNIVERSAL HEALTH SERVICES INCUHS | $11.2B | $194.07 | $17.4B | $1.5B | 20.5% | 0.65 | 11.5% | 1.05 | 4/9 | 6/9 | 5/7 | 1/3 | F-Score 7 | 6/11 |
| DAVITA INC.DVA | $11.0B | $174.56 | $13.6B | $746.8M | -114.7% | -15.78 | 15.0% | 1.29 | 1/9 | 4/9 | 2/7 | 1/3 | F-Score 7 | 3/11 |
| CHEMED CORPCHE | $7.1B | $548.20 | $2.5B | $265.2M | 27.1% | — | 13.4% | 1.05 | 4/9 | 7/9 | 3/7 | 1/3 | F-Score 6 | 6/11 |